| 1 | Negative-Pressure Aseptic Processing Isolator | High-containment sterile filling where operator and product protection are both required. | Negative pressure to the surrounding cleanroom; pressure cascade must be monitored and alarmed. | Unidirectional airflow over exposed critical zones; terminal HEPA filtration; airflow visualization and recovery testing required. | Validated rapid-transfer ports, interlocked doors, glove integrity testing, and validated bio-decontamination cycle. | Highly relevant
Can support Annex 1 contamination-control objectives when the complete system is qualified and validated. WHO guidance may be used as a risk-management reference, not as a product certificate. | Not normally applicable
NSF/ANSI 49 primarily covers Class II biosafety cabinets, not pharmaceutical isolators. | URS, risk assessment, airflow qualification, HEPA integrity test, glove leak test, smoke study, pressure-alarm test, decontamination-cycle validation, and environmental-monitoring plan. |
| 2 | Positive-Pressure Aseptic Compounding Isolator | Sterile compounding and small-batch aseptic preparation when product protection is the dominant requirement. | Positive pressure relative to the surrounding room; unsuitable for uncontrolled hazardous powders unless the design includes additional containment controls. | HEPA-filtered unidirectional or mixed airflow, depending on the validated process and internal layout. | Glove ports, material airlocks, pass-through chambers, validated surface disinfection, and defined material-flow segregation. | Highly relevant
May support EU GMP Annex 1 expectations for contamination control, personnel intervention reduction, and validated aseptic operations. | Not normally applicable
Do not claim NSF/ANSI 49 compliance unless a separately certified Class II cabinet is incorporated and assessed within its intended scope. | Cleanroom classification strategy, airflow-pattern study, pressure-cascade records, microbial-control strategy, cleaning validation, and aseptic-process simulation results. |
| 3 | Negative-Pressure Cytotoxic Compounding Isolator | Preparation of hazardous drugs, cytotoxic medicines, and other pharmaceutical compounds requiring operator protection. | Negative pressure relative to the room to reduce outward leakage during normal operation and foreseeable glove or door events. | Dedicated exhaust or safe-return design; HEPA filtration may be used, but chemical compatibility and exhaust treatment must be assessed. | Closed transfer devices, segregated waste routes, glove integrity testing, spill-management provisions, and validated decontamination. | Process-dependent
Annex 1 applies when sterile medicinal products are manufactured; WHO requirements depend on the product and national implementation. | Generally outside scope
NSF/ANSI 49 is not a general hazardous-drug isolator standard. | Hazardous-drug risk assessment, containment-performance data, exhaust calculations, chemical-compatibility data, decontamination validation, and operator-exposure monitoring where required. |
| 4 | Sterility-Testing Isolator | Pharmaceutical sterility testing and aseptic sample manipulation in a controlled enclosure. | Usually positive pressure for product protection; negative-pressure arrangements may be selected for special containment risks. | HEPA-filtered unidirectional airflow in the critical work zone; airflow velocity must be justified and validated for the design. | Rapid-transfer ports, validated disinfection or vapor-cycle decontamination, glove leak testing, and controlled sample introduction. | Highly relevant
Supports Annex 1 expectations when installed, qualified, and operated as part of a documented contamination-control strategy. | Not normally applicable
NSF/ANSI 49 should not be used as the primary compliance claim for this pharmaceutical isolator. | Installation and operational qualification, airflow visualization, recovery test, decontamination validation, media-fill strategy, environmental-monitoring qualification, and data-integrity controls. |
| 5 | Potent API Handling Isolator | Weighing, dispensing, sampling, and charging of highly potent active pharmaceutical ingredients. | Negative pressure with controlled airflow from cleaner areas toward the containment zone. | Low-turbulence local extraction, HEPA-filtered exhaust where appropriate, and containment verification at operator access points. | Split butterfly valves, contained transfer systems, bag-in/bag-out filters, glove ports, and validated cleaning procedures. | Process-dependent
EU GMP Annex 1 is relevant only when sterile product manufacture is involved; other GMP chapters and occupational-exposure controls may be more central. | Outside normal scope
NSF/ANSI 49 is not a potency-containment standard. | Occupational exposure limit assessment, surrogate containment test, airflow and leakage test, filter-loading assessment, cleaning-validation report, and maintenance containment procedure. |
| 6 | Class III Gas-Tight Microbiological Safety Isolator | Maximum personnel and environmental protection for high-risk biological agents and procedures requiring a sealed enclosure. | Negative pressure relative to the laboratory; the enclosure is operated as a gas-tight system with controlled exhaust. | Supply air is HEPA filtered; exhaust is normally HEPA filtered, often with redundant filtration depending on the risk assessment. | Pass-through autoclave or chemical dunk tank, sealed gloves or glove sleeves, leak testing, and controlled waste removal. | WHO-relevant
Risk-group, biosafety-level, and facility requirements must be determined from the agent and procedure. Annex 1 is generally not the governing standard. | Not covered as a Class II cabinet
NSF/ANSI 49 is primarily associated with Class II biosafety cabinets; Class III systems require different evidence and standards. | Leak-tightness test, pressure-decay or equivalent test, HEPA integrity test, exhaust verification, glove/sleeve integrity test, decontamination validation, and facility biosafety approval. |
| 7 | Cell and Gene Therapy Processing Isolator | Open processing steps involving cells, viral vectors, or other advanced-therapy materials. | Often positive pressure for product protection; negative or pressure-cascaded zones may be used for hazardous vectors or potent materials. | HEPA-filtered airflow designed around critical open manipulations; airflow must be demonstrated not to disrupt cells or process materials. | Closed-system connectors, rapid-transfer ports, single-use assemblies, validated decontamination, and electronic batch-record integration. | Highly relevant when sterile
Annex 1 contamination-control principles apply to sterile operations; WHO guidance may inform biosafety and quality-risk management. | Not normally applicable
NSF/ANSI 49 is not a complete qualification framework for advanced-therapy isolators. | Process-specific URS, aseptic-process simulation, airflow visualization, material and personnel-flow study, decontamination validation, cyber/data-integrity controls, and change-control records. |
| 8 | Anaerobic or Low-Oxygen Research Isolator | Culture, transfer, and incubation of anaerobic or oxygen-sensitive microorganisms. | Usually controlled positive pressure with an airlock; pressure selection depends on whether product protection or containment is primary. | Recirculating or once-through gas system; HEPA filtration may protect the room and internal process, but HEPA does not remove oxygen. | Gas-tight transfer chamber, oxygen and humidity monitoring, catalyst or gas-purge system, and validated recovery after door opening. | Limited relevance
WHO biosafety guidance may be relevant to the organisms; EU GMP Annex 1 applies only if the work forms part of sterile medicinal-product manufacture. | Not normally applicable
NSF/ANSI 49 does not certify anaerobic performance. | Oxygen-level mapping, leak test, gas-system qualification, alarm verification, biological containment assessment, and decontamination procedure. |
| 9 | Weighing and Dispensing Containment Isolator | Contained weighing, sampling, and dispensing of powders or granules in pharmaceutical and laboratory environments. | Negative pressure with inward airflow at glove ports and transfer openings. | Low-velocity capture airflow, HEPA-filtered exhaust, and airflow balancing designed to minimize powder migration and turbulence. | Contained docking systems, bag-in/bag-out filter change, continuous pressure monitoring, and cleanable internal surfaces. | Process-dependent
Annex 1 is relevant only for sterile-product operations; general GMP and occupational-containment requirements may apply instead. | Outside normal scope
NSF/ANSI 49 is not a powder-containment or pharmaceutical dispensing standard. | Containment-performance test, pressure and airflow records, filter integrity test, powder-residue assessment, cleaning validation, and occupational-exposure evaluation. |
| 10 | Class II Type A2 Biosafety Cabinet with Isolator-Style Enclosure | Routine microbiological, cell-culture, and low-to-moderate-risk laboratory work requiring personnel, product, and environmental protection. | Negative-pressure work zone with an inward airflow barrier at the front opening. | Vertical inflow and downflow air; supply and exhaust HEPA filtration; exhaust may be recirculated to the room or ducted according to the cabinet design and risk assessment. | Front sash, removable work tray, service access, and validated decontamination; it is not a fully sealed pharmaceutical isolator. | WHO-relevant
Appropriate selection depends on the biological risk assessment. EU GMP Annex 1 does not automatically apply to general laboratory cabinets. | Directly relevant
Class II Type A2 cabinets are within the principal scope of NSF/ANSI 49 when tested and certified under the applicable requirements. | Current NSF/ANSI 49 certification or equivalent recognized test evidence, onsite field certification, inflow/downflow measurements, HEPA integrity test, smoke-pattern test, and alarm verification. |
